ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
ARIAD Pharma (ARIA) Issued Brigatinib-Related U.S. Patent
April 22, 2015 7:36 AM EDTARIAD Pharma (NASDAQ: ARIA) announced the issuance of its first U.S. patent on brigatinib, ARIADs investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, Phosphorous Derivatives as Kinase Inhibitors. The patent provides composition-of-matter protection... More
